NCT05087303Completed
Telemedicine for Children With Sickle Cell Disease
Telemedicine for Pediatric Sickle Cell Patients in Medically Underserved Areas
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved. Aim 1: Adapt two telemedicine models (i.e., hub-and-spoke; direct-to-consumer) for use with children with SCD using caregiver input from our preliminary K12 work. Aim 2: Demonstrate the feasibility of the telemedicine models developed in Aim 1 as the models undergo successive stakeholder refinement during use in actual clinical care. Aim 3: Evaluate the effectiveness of the refined models from Aim 2 in a pre/post study by assessing (a) process of care measures, (b) provider satisfaction, (c) caregiver/patient-centered outcomes, and (d) clinical outcomes and healthcare utilization.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 15 Jun 2021
- Start date
- 23 Nov 2022
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Indiana University
- Diseases
- Sickle cell disease
- NCT number
- NCT05087303
What you commit to
- Study type: Interventional
- Participants enrolled: 24
- From 23 Nov 2022 to the primary completion date, 1 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- If a patient receives chronic transfusion therapy, they will not be eligible to participate, as our telemedicine models will not support this.
Who the study is looking for
- Caregivers must be 18 years or older, who have children between 0 to 21 years old with a diagnosis of Sickle Cell Disease and receive care at the Riley Hospital for Children Comprehensive Sickle Cell Disease clinic.
- Adolescent patients 16 years and older are also able to participate in interviews/surveys.
- The family must be willing to receive their care using the telemedicine model available to them based on the location of their primary residence.
- TeleSCD model participants must live within 1 hour of the pre-identified telemedicine sites, while VirtualSCD model participants must live within the city limits of the pre-identified area.
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Indiana University Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.